Cataract

Monofocal IOLs, along with advanced phacoemulsification technology, offer tailored solutions.

Shameema Sikder, MD; and T. Y. Alvin Liu, MD, highlight the technology’s role in bridging challenges and successes for clinical practice.

The state-of-the-art facility more than doubles the institute’s footprint, enhancing patient care, research, and education.

From easing fears to improving mood, a recent study explores how music transforms the surgical experience for both patients and health care teams.

Through its ophthalmic program, Mercy Ships provides critical eye surgeries and trains local professionals, ensuring sustainable eye care for the future.

According to the company, VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieved its primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treating post-operative inflammation following cataract surgery.

HelpMeSee’s Mazava Project trains general practitioners in Madagascar to perform cataract surgeries, addressing the country’s high rate of avoidable blindness. Trainees gain proficiency through simulation-based learning and live surgeries, improving access to eye care in remote areas.

HelpMeSee has partnered with new initiatives to address the global cataract blindness crisis, focusing on empowering women in low- and middle-income countries. Through training and education, the organization aims to reduce gender inequality and improve socioeconomic outcomes worldwide.

HelpMeSee has partnered with Empowered, an educational series hosted by Meg Ryan, to spotlight the cataract blindness crisis, its socioeconomic impacts, and gender inequality issues. The episode emphasizes simulation-based surgical training advancements, expanding cataract care access for underserved populations and fostering equitable healthcare solutions.

Analysis highlights discrepancies between adult, pediatric cataract procedures.

The integration of artificial intelligence in laser cataract technology is shifting the paradigm for the future of cataract surgery and is driving increased precision and improved outcomes for patients.

Investigators conducted a retrospective clinical database study that covered 12 years to quantify the risk of PCR in the second eye after PCR developed in the first eye during cataract surgery.

According to the company, there are no FDA-approved pharmacological therapies for age-related cataracts. Its C-KAD eye drop, improves vision in patients with early-to-moderate cataracts, by penetrating the eye to reduce lens clouding, the main cause for cataracts.

According to the company, enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks and more broadly in 2025. Bausch + Lomb is also in the process of seeking regulatory approvals for the lens in additional markets.

MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery.

The Gni instrument technology represents a significant innovation in ophthalmic surgery, particularly in cataract procedures, according to Gulani.

According to a team of researchers at the National Institutes of Health, their findings in animals suggest a surgery-free treatment for cataracts.

The drop improves vision by breaking up degraded protein complexes that cause lens clouding

The device features real-time feedback and other features, allowing residents to hone their skills and expand options for practicing one of the most needed procedures in the country.

The Summit will feature 18+ course hours and an extensive resource library to support practice adoption of AT IOLs

A team of researchers in China examined the difference and relationship between optical coherence tomography and optical quality analysis system parameters induced by compound electrolyte intraocular irrigating solution or Ringer lactate solution during uncomplicated cataract surgery.

According to the company, its combined vitreoretinal-cataract system and standalone cataract system are cleared for use in the United States.

Investigators looked to see if a large language model could provide safe, accurate, and readable information to patient inquiries about cataract surgery.

Over 380 organizations representing patients, health care providers, the medical technology and biopharmaceutical industry, health plans and others endorse the legislation

MELT-300 is a non IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg).

The organization is providing free cataract resources for patients and professionals, including fact sheets, social media graphics, a dedicated web page and expert video.

Abbreviated New Drug Applications seek potential approval of a generic drug product.

The AIOLIS will be used to clinically evaluate patients’ perception of visual disturbances following premium IOL cataract surgery.